This filing formalizes previously announced C-suite departures with no new financial surprises. Monitor the Q3 2026 10-Q for the full separation agreement exhibits and any updates on the strategic reorganization's impact on headcount and cash burn.
Price Chart
Executive Summary
TScan Therapeutics formalized separation agreements with former CFO Jason Amello and former CMO Chrystal Louis, previously announced as part of a September 2, 2026 strategic reorganization. Both executives will remain on payroll through the earlier of November 1, 2026 or new employment commencement, with base salary and benefits continuing. Each is eligible for milestone-based retention awards ($85,000 for Amello, $125,000 for Louis) under the November 2025 retention program. This is a routine administrative step in an already-disclosed restructuring, no new surprise departures or financial terms.
Key Facts
- CFO Jason Amello and CMO Chrystal Louis departures were previously disclosed on September 2, 2026 as part of a strategic reorganization
- Separation agreements executed September 24 (Louis) and September 25 (Amello), 2026
- Employment terminates on earlier of November 1, 2026 or start of new employment/consulting/board service
- Base salary and benefits continue through separation date
- Amello eligible for $85,000 milestone-based lump sum under November 2025 retention program
- Louis eligible for $125,000 milestone-based lump sum under November 2025 retention program
- Separation agreements to be filed as exhibits to Q3 2026 10-Q
Financial Impact
Up to $210,000 in contingent milestone payments ($85,000 to Amello, $125,000 to Louis) if certain Company milestones achieved before separation; ongoing salary/benefits through ~November 1, 2026 for both executives
Risk Factors
- Key executive departures may slow clinical development and regulatory timelines
- Milestone-based retention payments create modest cash outflow if milestones are achieved
- Further organizational disruption possible as strategic reorganization continues
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-409199 |
| Document: 0001193125-26-409199-index-headers.html | 0001193125-26-409199 |
| Document: 0001193125-26-409199-index.html | 0001193125-26-409199 |
| Document: 0001193125-26-409199.txt | 0001193125-26-409199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 3d ago | DEF 14A | $0.1897 | awaiting T+20 | awaiting T+20 | $0.1950 (−2.79%) |
Oct 16, 2026 13d ago | 8-K | $0.2102 | awaiting T+20 | awaiting T+20 | $0.1950 (−7.23%) |
Sep 30, 2026 29d ago | 8-K | $0.3175 $0.1949 | ▼ −38.61% | ▼ −39.32% | $0.1950 (−38.58%) |
Sep 25, 2026 4w ago | SC 13G | $0.3400 $0.1897 | ▼ −44.21% | ▼ −44.17% | $0.1950 (−42.65%) |
Sep 11, 2026 6w ago | 8-K | $0.3204 $0.2380 | ▼ −25.72% | ▼ −27.59% | $0.1950 (−39.14%) |
Sep 2, 2026 8w ago | 8-K | $0.3810 $0.3150 | ▲ +17.32% | ▲ +17.24% | $0.1950 (+48.82%) |
Aug 18, 2026 10w ago | 8-K | $0.7500 $0.3335 | ▲ +55.53% | ▲ +53.58% | $0.1950 (+74.00%) |
Aug 12, 2026 11w ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Aug 12, 2026 11w ago | Press Release | $0.7730 $0.3179 | ▲ +58.87% | ▲ +56.98% | $0.1950 (+74.77%) |
Jun 22, 2026 18w ago | 8-K | $0.8651 $0.9148 | ▲ +5.75% | ▲ +5.89% | $0.1950 (−77.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers